TWI354572B - Methods for stem cell enrichment by the use of tan - Google Patents

Methods for stem cell enrichment by the use of tan Download PDF

Info

Publication number
TWI354572B
TWI354572B TW093136123A TW93136123A TWI354572B TW I354572 B TWI354572 B TW I354572B TW 093136123 A TW093136123 A TW 093136123A TW 93136123 A TW93136123 A TW 93136123A TW I354572 B TWI354572 B TW I354572B
Authority
TW
Taiwan
Prior art keywords
stem cell
tan
methods
cell enrichment
sample
Prior art date
Application number
TW093136123A
Other languages
English (en)
Other versions
TW200524647A (en
Inventor
Marnix L Bosch
Patricia A Lodge
Julie Anne Mcearchern
Alton L Boynton
Paul G Hugenholtz
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of TW200524647A publication Critical patent/TW200524647A/zh
Application granted granted Critical
Publication of TWI354572B publication Critical patent/TWI354572B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D35/00—Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
    • B01D35/05—Floating filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Description

1354572 1〇1年8月之4·曰修正替換頁 18、 根據申請專利範圍第μ項之方法~~-- 再中邊生理可 接受之溶液係低離子強度。 19、 根據申請專利範圍第13項之方 具中该前處理 包括使細胞接觸生理可接受含甘油之溶液。 20、 根據申請專利範圍第19項之方法，其中該甘油濃 度在 0.5mol/L 與 2.5mol/L 之間。 21、 根據申請專利範圍第19項之方法，其中該甘油濃 度係 1 mol/L。 22、 根據申請專利範圍第14項之方法，其中顆粒性白 # 血球經由細胞溶解優先自細胞混合物中移除。 23、 根據申請專利範圍第22項之方法，其中細胞溶解 可由樣本對有效量之DMS〇及甘油之依序接觸而達到。 24、 根據申請專利範圍第23項之方法，其中該樣本之 接觸係與低滲透壓強度之溶液。 25 一種虽集骨髓或血液成分樣本中幹細胞之方法， 包括： (^ )將樣本導入切向流式過遽（TFF )單位，該TFF 鲁 單位包括一交互流式槽、一過濾液槽，以及一與交互流式 槽和過濾液槽液體流通之過濾器，過濾器之孔洞大小約丄 至1 〇微米； (11)使該樣本經由切向流式過濾（TFF)單位以預設 定好之，主入速率及過濾速率進行再循環，該預設定好之注 入速率至少係預設定好之過濾速率五倍；其中該預設之過 遽速率小於無競爭之過濾速率；和 38 1354572 101年8月砰曰修正替換頁 (i i i )分離富集幹細胞之細胞族群。 26、 根據申請專利範圍第25項之方法，其中該富集幹 細胞之細胞族群大體上不含非白血球細胞之血液組成。 27、 根擄申請專利範圍第25項之方法，進一步包括將 虽集幹細胞之細胞族群施予個體之步驟。 28、 根擄申請專利範圍第27項之方法，其中該樣本係 來自至少以一種幹細胞活動試劑治療之受試者。 29、 根擄申請專利範圍第28項之方法，其中該幹細胞 活動試劑包括M-CSF、G-CSF、GM-CSF或環磷醯胺。 讀 3〇、根據申請專利範圍第27項之方法，其中該幹細胞 係再注射回接受者。 31、根據申請專利範圍第3〇項之方法，其中該接受者 與受試者係自體或異體。 ,32、根據申請專利範圍第30項之方法，其中該接受者 系而要月趟重健、係需要心臟組織修復、受過骨趙摧毀治 療、士歷過心肌梗塞、係患有充血性心臟衰竭、或係患有 心臟功能不足。 | 么33、根據申請專利範圍第30項之方法，其中該富集幹 、田胞紅群係庄射到循環系統、係注射入冠狀動脈、 或係直接塗敷於受損心臟組織。 39
TW093136123A 2003-11-24 2004-11-24 Methods for stem cell enrichment by the use of tan TWI354572B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52451103P 2003-11-24 2003-11-24

Publications (2)

Publication Number Publication Date
TW200524647A TW200524647A (en) 2005-08-01
TWI354572B true TWI354572B (en) 2011-12-21

Family

ID=34632903

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093136123A TWI354572B (en) 2003-11-24 2004-11-24 Methods for stem cell enrichment by the use of tan

Country Status (14)

Country Link
US (1) US7790039B2 (zh)
EP (1) EP1689855A4 (zh)
JP (2) JP2007512814A (zh)
KR (1) KR20070055416A (zh)
CN (2) CN102321573B (zh)
AR (1) AR047043A1 (zh)
AU (1) AU2004293794B2 (zh)
BR (1) BRPI0416898A (zh)
CA (1) CA2546349C (zh)
CR (1) CR8414A (zh)
IL (1) IL175530A (zh)
RU (1) RU2006122038A (zh)
TW (1) TWI354572B (zh)
WO (1) WO2005052137A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678250B (zh) * 2007-03-02 2013-04-24 史密夫及内修公开有限公司 用于在生物样品过滤中通过超声、回洗和过滤器运动进行过滤器清洁的装置和方法
CN101801431B (zh) * 2007-06-22 2014-11-19 循环生物制品有限责任公司 流体浓缩器和自体浓缩体液及其使用方法
KR100867942B1 (ko) * 2007-08-09 2008-11-10 콘티넨탈 오토모티브 일렉트로닉스 주식회사 차량용 에이비에스 센서의 리드프레임 구조
US8420392B2 (en) * 2007-08-23 2013-04-16 Niigata University Method for culturing human periosteum
FR2931081B1 (fr) * 2008-05-14 2010-06-25 Direction Et Pirorites Dispositif de filtration d'un liquide complexe tel que du sang, notamment applicable a un autotransfuseur
US8546127B2 (en) * 2008-06-30 2013-10-01 General Electric Company Bacteria/RNA extraction device
WO2010010355A2 (en) 2008-07-25 2010-01-28 Smith & Nephew Plc Controller for separation apparatus
CA2755887C (en) * 2009-03-30 2014-02-04 Daiichi Sankyo Company, Limited Method for inducing cell death in pluripotent stem cells and differentiated cells other than cardiac myocytes
US20100291534A1 (en) * 2009-05-12 2010-11-18 National Central University Methods and Systems for Isolating, Ex Vivo Expanding and Harvesting Hematopoietic Stem Cells
DK2548950T3 (en) 2009-06-05 2017-12-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
AU2010336424B2 (en) 2009-12-23 2013-06-13 Cytovera, Inc. A system and method for particle filtration
AU2013204820B2 (en) * 2009-12-23 2014-01-30 Cytovera, Inc. A System and Method for Particle Filtration
CN101851606B (zh) * 2010-04-07 2012-05-30 魏红江 卵丘-卵母细胞复合体刀切过滤法
CN102260628A (zh) * 2010-05-31 2011-11-30 上海康德莱企业发展集团医疗器械有限公司 一种干细胞过滤筛选富集并快速复合装置
JP2012080821A (ja) * 2010-10-12 2012-04-26 Univ Of Tsukuba 血液中の有核細胞成分濃縮方法
GB201106802D0 (en) * 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
CN102212461B (zh) * 2011-05-05 2013-04-17 中国人民解放军第二炮兵总医院 间充质干细胞过滤分离器及其应用
US9422526B2 (en) 2011-06-14 2016-08-23 The University Of North Carolina At Chapel Hill Isolation, expansion and use of autologous pluripotent stem cells
US10934519B2 (en) 2011-07-29 2021-03-02 Global Life Sciences Solutions Usa Llc Systems, methods and control laws for cell harvesting
US9421317B2 (en) * 2012-06-08 2016-08-23 Pall Corporation Cell harvesting device and system
US9427512B2 (en) 2012-06-08 2016-08-30 Pall Corporation Filter device
SG11201408169YA (en) * 2012-12-14 2015-01-29 Chong Zheng Centrifugal dynamic filtering apparatus and cell separation system using same
EP2931330A1 (en) * 2012-12-14 2015-10-21 BHC Technology Holdings LLC Point of care isolation and concentration of blood cells
JP6387019B2 (ja) * 2013-02-01 2018-09-05 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法
JP2016518415A (ja) * 2013-10-21 2016-06-23 アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
EP3248004B1 (en) * 2015-01-21 2020-10-07 Agency For Science, Technology And Research Rare cells and uses thereof
CN105713870A (zh) * 2016-03-04 2016-06-29 佰通生物技术(苏州)有限公司 一种基于集落刺激因子1对干细胞的活化方法
CN110035702A (zh) * 2016-10-24 2019-07-19 耶鲁大学 穿刺装置
CN112342192B (zh) * 2020-10-27 2022-08-05 北京唐颐惠康生物医学技术有限公司 一种连续切向流干细胞分离纯化方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4240398A (en) * 1978-10-05 1980-12-23 Lindop Arthur H Cleaning device for cooker grills
US4420398A (en) * 1981-08-13 1983-12-13 American National Red Cross Filteration method for cell produced antiviral substances
US4888115A (en) 1983-12-29 1989-12-19 Cuno, Incorporated Cross-flow filtration
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
GB2176715A (en) 1985-06-27 1987-01-07 Apv Int Ltd Beer filtration
US4722902A (en) * 1985-11-04 1988-02-02 Endotronics, Inc. Apparatus and method for culturing cells, removing waste and concentrating product
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5423738A (en) * 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
NL9301653A (nl) * 1993-09-24 1995-04-18 X Flow Bv Werkwijze voor het verwijderen van troebelheid veroorzakende bestanddelen uit een vloeistof met behulp van microfiltratie.
US6984379B1 (en) * 1994-04-08 2006-01-10 Children's Hospital of LosAngeles Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6140040A (en) * 1995-10-06 2000-10-31 Advanced Minerals Corporation Method of mechanically separating microparticles suspended in fluids using particulate media
WO1997015380A1 (en) * 1995-10-23 1997-05-01 Hemasure, Inc. Extra-lumenal crossflow plasmapheresis devices
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
CA2261612A1 (en) * 1996-08-26 1998-03-05 Hemasure, Inc. Method for removing tumor cells from tumor cell-contaminated stem cell products
DE19650648A1 (de) * 1996-12-06 1998-06-10 Sartorius Gmbh Wickelmodul
US6183640B1 (en) * 1999-04-09 2001-02-06 Usf Filtration And Separations Group, Inc. Highly asymmetric anionic membranes
IL147644A0 (en) * 1999-07-23 2002-08-14 Genentech Inc Method for rnase-and organic solvent-free plasmid dna purification using tangential flow filtration
CN1298949A (zh) * 1999-12-07 2001-06-13 刘宏宇 一种由酵母菌(Pichia pastoris)制备人体血清白蛋白的方法
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
EP1289630B1 (de) * 2000-03-07 2008-03-05 MAT Adsorption Technologies GmbH & Co. KG Modul mit membranelementen in cross-flow und in dead-end anordnung
US6455306B1 (en) * 2000-06-09 2002-09-24 Transcyte, Inc. Transfusable oxygenating composition
JP4407996B2 (ja) * 2000-06-15 2010-02-03 サンデン株式会社 コイン払出装置
KR100809489B1 (ko) * 2001-10-10 2008-03-03 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난4'-메탄설포닐-비페닐 유도체
WO2003031938A2 (en) * 2001-10-11 2003-04-17 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
JP2003320011A (ja) * 2002-04-30 2003-11-11 Olympus Optical Co Ltd 生体組織補填材、生体組織補填体、生体組織補填体の製造方法及び生体組織補填体の製造装置
DK1517740T3 (en) * 2002-06-19 2019-04-15 Northwest Biotherapeutics Inc Tangential Flow Filtering Devices and Methods for Leukocyte Enrichment
TW200506061A (en) 2003-02-27 2005-02-16 Northwest Biotherapeutics Inc Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Also Published As

Publication number Publication date
CN102321573B (zh) 2015-01-14
CN1886498A (zh) 2006-12-27
CA2546349C (en) 2015-07-07
US20050189297A1 (en) 2005-09-01
IL175530A (en) 2012-07-31
JP2011182803A (ja) 2011-09-22
CN1886498B (zh) 2013-10-30
KR20070055416A (ko) 2007-05-30
AU2004293794A1 (en) 2005-06-09
JP5343110B2 (ja) 2013-11-13
EP1689855A4 (en) 2008-04-16
CA2546349A1 (en) 2005-06-09
BRPI0416898A (pt) 2007-03-06
IL175530A0 (en) 2006-09-05
WO2005052137A1 (en) 2005-06-09
TW200524647A (en) 2005-08-01
CN102321573A (zh) 2012-01-18
AU2004293794B2 (en) 2011-06-02
US7790039B2 (en) 2010-09-07
AR047043A1 (es) 2006-01-04
RU2006122038A (ru) 2008-01-10
JP2007512814A (ja) 2007-05-24
CR8414A (es) 2006-11-23
EP1689855A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
TWI354572B (en) Methods for stem cell enrichment by the use of tan
JP2007512814A5 (zh)
Bonforte et al. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid
NL194909C (nl) Werkwijze voor de bereiding van gepolymeriseerd hemoglobine en celvrij vervangingsmiddel voor rode bloedlichaampjes op basis daarvan.
Gejyo et al. Current clinical and pathogenetic understanding of β2‐m amyloidosis in long‐term haemodialysis patients
Lin et al. Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients
JPH0466455B2 (zh)
Ronco et al. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove ß2-microglobulin in hemodialysis
Ramirez et al. Inflammation and hemodiafiltration
JP2012505239A5 (zh)
de Francisco et al. Challenges and future of renal replacement therapy
CN201123923Y (zh) 一种可治疗多器官功能障碍综合症的混合型人工肝系统
DE19854338A1 (de) Verfahren und Einrichtung zur Nierenersatztherapie
WO2014178438A1 (ja) 毛髪再生用の細胞製剤
Sampaio et al. Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis
EP1951337B1 (en) Extracorporeal blood cleaning
ITBO940436A1 (it) Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
CN102458501A (zh) 透析装置
EP3603691B1 (en) Dialysate for hemodialysis
Felldin et al. Treatment with the molecular adsorbent recirculating system in patients with acute liver failure
CN116270451A (zh) 一种新鲜间充质干细胞注射液及其制备方法
Delano et al. Home and medical center hemodialysis: Dollar comparison and payback period
Ronco et al. Solute and water transport during continuous arteriovenous hemofiltration (CAVH)
Hyver et al. An in vivo analysis of reverse ultrafiltration during high-flux and high-efficiency dialysis
Canaud et al. Ultrafiltration and convective-based dialysis modalities: new trends and applications for renal replacement therapy in ESRD patients

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees